The Pentagon considers the offshoring of generic drug manufacturing a national security threat because of the resulting dependence on Chinese pharmaceutical ingredients. This initiative aims to bring critical supply chains back to the United States and reduce the dominance of foreign suppliers in the domestic pharmaceutical sector.
